Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,721.50
(
0.33%
)
US TECH 100
24,104.04
(
0.37%
)
Dow Jones
47,063.09
(
0.25%
)
Brent Oil
99.18
(
0.90%
)
Bitcoin
74,177.30
(
-0.89%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

randychub

Send PM Follow Ignore
Followers 24
Posts 2702
Boards Moderated 0
Alias Born 10/23/2003

randychub

Re: DewDiligence post# 106553

Monday, 10/18/2010 10:22:26 PM

Monday, October 18, 2010 10:22:26 PM

Post# of 257251
Bicon - I see part of their Robust product line includes BIOMAb-EGFR™. This is same EGFR drug (nimotuzumab) YMI is very slowly developing.

- BIOMAb EGFR® voted ‘Bio-Spectrum Asia-Pacific Product of the year’, 2008

The sales of diabetology division increased by 24 per cent, oncology segment by 59 per cent with brand Abraxane and Biomab EGFR as key contributors.


R
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now